Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 7/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.38 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.38 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381766 | 0.90 | DRD2 (0.42) | HDAC1DRD2DRD3JAK2BRD4 | |
| SCHEMBL6503950 | 0.87 | DRD2 (0.40) | HDAC1DRD2DRD3JAK2BRD4 | |
| SCHEMBL383373 | 0.85 | ITGB3 (0.40) | HDAC1 | |
| SCHEMBL381828 | 0.84 | DRD2 (0.43) | DRD2DRD3 | |
| SCHEMBL6499251 | 0.82 | SFRP1 (0.42) | HDAC1DRD2DRD3JAK2BRD4 | |
| SCHEMBL6499250 | 0.81 | VCP (0.40) | HDAC1DRD2DRD3SCN9AVCP | |
| SCHEMBL7464438 | 0.80 | DRD2 (0.42) | HDAC1DRD2DRD3SCN9APLOD2 | |
| SCHEMBL383200 | 0.79 | DRD2 (0.34) | HDAC1DRD2DRD3 | |
| SCHEMBL6497223 | 0.79 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL6501602 | 0.78 | KDM4E (0.56) | DRD2DRD3PLOD2PLOD3PLOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | HDAC1 739/4885DRD2 796/4885DRD3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.